HER2 Breast Cancer

Trastuzumab deruxtecan was safe and efficacious prior to treatment with paclitaxel, trastuzumab, and pertuzumab.

This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Pyrotinib is a tyrosine kinase inhibitor that is independently developed in China.

Patients in both arms achieved statistically significant rates of compliance up to 97%.

PAK5 is a protein that drives resistance to trastuzumab emtansine in patients with HER2+ breast cancer.

The meaningful results were reported in the DESTINY-Breast09 trial.

Sequencing of antibody-drug conjugates (ADCs) in HER2-mutated breast cancer is crucial for optimizing treatment outcomes.

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

The data showed improvements in overall response rates, progression-free survival, and duration of response.

Imlunestrant is an investigational, brain-penetrating, oral selective degrader of estrogen receptor.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

The predictive tool may reveal the mechanisms underlying treatment resistance in patients with HER+ breast cancer.

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

Camizestrant is an investigational oral selective estrogen receptor degrader.

Patients achieved an overall survival of 12.4 months.

Tanshinlactone is an active ingredient that is commonly used in Chinese herbal medicine.

T-DXd has a boxed warning for interstitial lung disease and pneumonitis.

Presence of leptomeningeal disease is associated with poorer treatment outcomes and quality of life for patients with breast cancer.

In the study, 50% of the deaths amongst patients were linked to central nervous system-related causes.

The diagnostic identifies patients who may be eligible for treatment with fam-trastuzumab-deruxtecan-nxki (Enhertu; Daiichi-Sankyo, AstraZeneca).

Continuous dosing of ribociclib was associated with better tolerability and outcomes.

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.

The overall survival data were immature at the primary analysis of the study.